Database : MEDLINE
Search on : Pemphigus [Words]
References found : 8435 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 844 go to page                         

  1 / 8435 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29521637
[Au] Autor:Kridin K; Zelber-Sagi S; Bergman R
[Ad] Address:Department of Dermatology, Rambam Health Care Campus.
[Ti] Title:Risk factors for lethal outcome in patients with pemphigus: a retrospective cohort study.
[So] Source:Eur J Dermatol;28(1):26-37, 2018 Feb 01.
[Is] ISSN:1952-4013
[Cp] Country of publication:France
[La] Language:eng
[Ab] Abstract:Although pemphigus is associated with increased mortality, little is known regarding factors that influence prognosis. To identify prognostic factors for mortality at five- and 10-year periods after an initial diagnosis of pemphigus. A retrospective cohort study was performed. Data were collected for all patients with a new diagnosis of pemphigus between 1990 and 2011, who were actively followed for at least five years at our centre. The endpoint was overall survival at five and 10 years after pemphigus diagnosis. Based on the test sample, associations between clinical variables and overall survival were assessed using univariate and multivariate analyses. A total of 184 patients were included in the study (mean age: 52.2 ± 16.1). The major risk factors for lethal outcome at both five and 10 years after diagnosis were age ≥65 years at diagnosis (with a multivariate hazard ratio [HR] of 5.9 and 4.2 at five and 10 years, respectively) and neurological disease at diagnosis (with a multivariate HR of 5.4 and 5.1 at 5 and 10 years, respectively). Diabetes mellitus was an independent risk factor for mortality at five years (multivariate HR: 3.8). Two risk factors were independently associated with lethal outcome at 10 years: serum albumin levels <3.5 g/dL (multivariate HR: 3.3) and lung disease at diagnosis (multivariate HR: 3.8). Mucosal involvement in patients with pemphigus vulgaris was not associated with increased mortality. Prognosis of patients with pemphigus is influenced by older age, hypoalbuminaemia, diabetes mellitus, and neurological and respiratory comorbidities at diagnosis.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process
[do] DOI:10.1684/ejd.2018.3252

  2 / 8435 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29278440
[Au] Autor:Schmidt T; Mauracher S; Bender L; Greene B; Kurzhals J; Eming R; Dostatni R; Hertl M
[Ad] Address:Department of Dermatology and Allergology, Philipps-University, Marburg, Germany.
[Ti] Title:A novel lateral flow immunoassay for the rapid detection of anti-Dsg3 IgG serum autoantibodies in pemphigus vulgaris.
[So] Source:Exp Dermatol;27(3):233-237, 2018 Mar.
[Is] ISSN:1600-0625
[Cp] Country of publication:Denmark
[La] Language:eng
[Ab] Abstract:Pemphigus vulgaris (PV) is a severe autoimmune blistering disease of the skin and mucous membranes. As autoantibodies play an essential role in the disease pathogenesis, the serological detection of anti-desmoglein 3 IgG represents a central tool in the diagnosis of the disease. In this study, we show the validation of a novel lateral flow immunoassay (LFIA) which rapidly detects anti-desmoglein 3 (Dsg3) IgG in human serum. In contrast to other diagnostic procedures, the assay is compact and simple to perform and delivers a fast "yes" or "no" answer within 10 minutes without additional hardware requirements for test evaluation. For validation, a blinded collection of 200 sera including 100 sera from 14 PV patients, 75 sera from 24 bullous pemphigoid patients and 25 sera from 6 patients with pemphigus foliaceus collected at different time points during disease was used. Presence or non-presence of anti-Dsg3 IgG within sera was confirmed using a commercially available Dsg3-ELISA. For qualitative evaluation, Dsg3-LFIA test results were assessed by two independent groups of human observers. Furthermore, quantitative evaluation using POCScan reader was applied. The Dsg3-LFIA demonstrated reliable test results with a sensitivity and specificity of 78.1% and 97.1%, respectively. Test results from POCScan and human observers showed a substantial agreement. The Dsg3-LFIA represents a new diagnostic tool for the immediate and reliable detection of anti-desmoglein 3 serum IgG autoantibodies that does not require additional hardware. Further prospective trials are warranted to validate the Dsg3 LFIA in pemphigus.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Data-Review
[do] DOI:10.1111/exd.13488

  3 / 8435 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29237064
[Au] Autor:Walsh P; Brochado MJF; Vernal S; Machado AR; Turatti A; de Paula NA; Donadi EA; Roselino AM
[Ad] Address:Division of Dermatology, Department of Clinical Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, 14049-900, São Paulo.
[Ti] Title:Relationship between pemphigus and American tegumentary leishmaniasis: insights from serological and genetic profiles.
[So] Source:Trans R Soc Trop Med Hyg;111(8):345-353, 2017 Aug 01.
[Is] ISSN:1878-3503
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Background: Antibodies against Leishmania peptides (Lbr-peps) and desmogleins (Dsgs) have been reported in pemphigus foliaceus (PF) and leishmaniasis patients, respectively. We aimed to compare serological and genetic features in a Brazilian region endemic for American tegumentary leishmaniasis (ATL) and pemphigus. Methods: Commercial anti-Dsg ELISA and in-house ELISA with Lbr-peps were used to determine the serological profile, in addition to immunoblotting (IB) and indirect immunofluorescence (IIF) assays. HLA-DRB1 and -DQA1/DQB1 alleles were characterized by PCR combined with sequence-specific oligonucleotide probes (PCR-SSOP). The serological and genetic profiles were compared using 78 PF, 62 pemphigus vulgaris (PV) and 58 ATL patients against 163 and 1592 healthy controls, respectively. Results: Some ATL patients showed positive results for anti-Dsg1 and/or anti-Dsg3 antibodies. They also revealed 130, 160 and/or 230 kDa epidermal peptides in IB. Moreover, some ATL samples exhibited pemphigus or a bullous pemphigoid pattern in IIF. ELISA and IB assays showed Lbr-peps in pemphigus patients. HLA-DQA1*01 and -DQA1*01:02 were protective and susceptibility alleles for ATL, respectively, but the opposite for pemphigus. Conclusions: Anti-Dsgs in ATL may represent epiphenomena. Anti-Lbr-pep antibodies in pemphigus suggest a previous infection. A differential association of the HLA profile may contribute to the lack of co-association between pemphigus and ATL.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review
[do] DOI:10.1093/trstmh/trx065

  4 / 8435 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29157619
[Au] Autor:Szalat R; Munshi NC
[Ad] Address:Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, M230 Boston, MA 02215, USA.
[Ti] Title:Diagnosis of Castleman Disease.
[So] Source:Hematol Oncol Clin North Am;32(1):53-64, 2018 02.
[Is] ISSN:1558-1977
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Castleman disease (CD) is a rare and heterogenous group of disorders sharing in common an abnormal lymph node pathology. CD comprises distinct subtypes with different prognoses. Unicentric CD and multicentric CD are featured by specific systemic manifestations and may be associated with Kaposi sarcoma, non-Hodgkin and Hodgkin lymphoma, and POEMS syndrome. Multicentric CD is classically associated with systemic symptoms and poorer prognosis. In this article, the authors review how to diagnose the disease, keeping in context the clinical findings, biochemical changes and complications associated with CD.
[Mh] MeSH terms primary: Castleman Disease/diagnosis
Castleman Disease/pathology
Lymph Nodes/pathology
[Mh] MeSH terms secundary: Hodgkin Disease/diagnosis
Hodgkin Disease/pathology
Humans
Lymphoma, Non-Hodgkin/diagnosis
Lymphoma, Non-Hodgkin/pathology
POEMS Syndrome/diagnosis
POEMS Syndrome/pathology
Sarcoma, Kaposi/diagnosis
Sarcoma, Kaposi/pathology
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1801
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[Js] Journal subset:IM
[Da] Date of entry for processing:171122
[St] Status:MEDLINE

  5 / 8435 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29512980
[Au] Autor:Giannetti L; Generali L; Bertoldi C
[Ad] Address:Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con Interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, Università degli Studi di Modena e Reggio Emilia, Modena, Italy - Luca.giannetti@unimore.it.
[Ti] Title:Oral pemphigus.
[So] Source:G Ital Dermatol Venereol;, 2018 Mar 06.
[Is] ISSN:1827-1820
[Cp] Country of publication:Italy
[La] Language:eng
[Ab] Abstract:Involvement of the oral mucosa in patients affected by Pemphigus Vulgaris (PV), Paraneoplastic, IgA Pemphigus and in some cases of Iatrogenic Pemphigus is common, and precede skin lesions in the majority of cases. Intraepidermal bullae are caused by acantholysis, induced by IgG autoantibodies directed against the desmosomes and the domain of numerous keratinocytes self-antigens desmogleins (namely cadherins), thus supporting the autoimmune nature of the disease. Apoptosis may contribute to the acantholysis.The oral mucosal lesions tend more often to be refractory to treatment than skin lesions, and have been associated with disease duration, disease location and possibly the presence of HSV DNA in the oral cavity. Recent publications have stressed the positive role of Rituximab in early disease treatment.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:Publisher
[do] DOI:10.23736/S0392-0488.18.05887-X

  6 / 8435 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29369789
[Au] Autor:Lee HC; Melduni RM
[Ad] Address:Heart Rhythm Division, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: lee.honchi@mayo.edu.
[Ti] Title:Autoimmunity and cardiac arrhythmias in endemic pemphigus foliaceus-Association, correlation, or causation?
[So] Source:Heart Rhythm;, 2018 Jan 31.
[Is] ISSN:1556-3871
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:EDITORIAL
[Em] Entry month:1801
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:Publisher

  7 / 8435 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29301743
[Au] Autor:Dowlatshahi EA; Diercks G; van Doorn M
[Ad] Address:Erasmus Medical Centre, Rotterdam, Netherlands emmilia.dowlat@gmail.com.
[Ti] Title:Blisters in disguise.
[So] Source:BMJ;360:j5364, 2018 01 04.
[Is] ISSN:1756-1833
[Cp] Country of publication:England
[La] Language:eng
[Mh] MeSH terms primary: Blister/immunology
Blister/pathology
Pemphigus/immunology
Pemphigus/pathology
Skin/pathology
[Mh] MeSH terms secundary: Adrenal Cortex Hormones/administration & dosage
Adrenal Cortex Hormones/therapeutic use
Aged
Blister/drug therapy
Blister/epidemiology
Desmogleins/immunology
Diagnosis, Differential
Enzyme-Linked Immunosorbent Assay/methods
Fluorescent Antibody Technique, Direct/methods
Humans
Immunologic Factors/administration & dosage
Immunologic Factors/therapeutic use
Immunosuppressive Agents/administration & dosage
Immunosuppressive Agents/therapeutic use
Incidence
Male
Pemphigus/drug therapy
Pemphigus/epidemiology
Rituximab/administration & dosage
Rituximab/therapeutic use
Skin/immunology
Treatment Outcome
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (Adrenal Cortex Hormones); 0 (Desmogleins); 0 (Immunologic Factors); 0 (Immunosuppressive Agents); 4F4X42SYQ6 (Rituximab)
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180106
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.j5364

  8 / 8435 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29501254
[Au] Autor:Kridin K; Comaneshter D; Batat E; Cohen AD
[Ad] Address:Department of Dermatology, Rambam Health Care Campus, Haifa, Israel. Electronic address: dr_kridin@hotmail.com.
[Ti] Title:COPD and lung cancer in patients with pemphigus- a population based study.
[So] Source:Respir Med;136:93-97, 2018 Mar.
[Is] ISSN:1532-3064
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Recent evidence indicates that autoimmunity may contribute to the pathogenesis of chronic obstructive pulmonary disease (COPD). COPD was observed at higher frequency in patients with several autoimmune diseases. The association between pemphigus and COPD has not been evaluated in the past. OBJECTIVES: To study the association between pemphigus and COPD using a large-scale real-life computerized database. METHODS: A cross-sectional study was conducted comparing pemphigus patients with age-, sex- and ethnicity-matched control subjects regarding the prevalence of COPD and lung cancer. Chi-square and t-tests were used for bivariate analysis, and logistic regression model was used for multivariate analysis. The study was performed utilizing the computerized database of Clalit Health Services ensuring 4.4 million subjects. RESULTS: A total of 1985 pemphigus patients and 9874 controls were included in the study. The prevalence of COPD was greater in patients with pemphigus as compared to the control group (13.4% vs. 10.1%, respectively; P < 0.001). In a multivariate analysis adjusting for smoking and other confounding factors, pemphigus was significantly associated with COPD (OR, 1.312-1. 5) but not with lung cancer. Study findings were robust to sensitivity analysis that included patients under pemphigus-specific treatments. CONCLUSIONS: A significant association was found between COPD and pemphigus. Physicians treating patients with pemphigus might be aware of this possible association. This observation may further support the hypothesis that COPD has an autoimmune component.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180304
[Lr] Last revision date:180304
[St] Status:In-Data-Review

  9 / 8435 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29289266
[Au] Autor:Trop-Steinberg S; Azar Y
[Ad] Address:Faculty of Life and Health Sciences (ST-S), JCT Lev Academic Institute, Jerusalem, Israel. Electronic address: shivtia@g.jct.ac.il.
[Ti] Title:Is Myc an Important Biomarker? Myc Expression in Immune Disorders and Cancer.
[So] Source:Am J Med Sci;355(1):67-75, 2018 Jan.
[Is] ISSN:1538-2990
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The proto-oncogene Myc serves as a paradigm for understanding the dynamics of transcriptional regulation. Myc protein has been linked to immune dysfunction, cancer development and neoplastic transformation. We review recent research regarding functions of Myc as an important modulator in immune disorders, postallogeneic hematopoietic stem cell transplantation (HSCT) and several cancers. Myc overexpression has been repeatedly linked to immune disorders and specific cancers, such as myasthenia gravis, psoriasis, pemphigus vulgaris, atherosclerosis, long-term allogeneic survival among HSCT patients, (primary) inflammatory breast cancer, (primary) ovarian carcinoma and hematological malignancies: acute myeloid leukemia, chronic myelogenous leukemia, Hodgkin's lymphoma and diffuse large B-cell lymphoma. However, decreased expression of Myc has been observed in HSCT patients who did not survive. Understanding impaired or inappropriate expression of Myc may present a path for the discovery of new targets for therapeutic applications.
[Mh] MeSH terms primary: Biomarkers, Tumor/biosynthesis
Gene Expression Regulation, Neoplastic
Immune System Diseases/metabolism
Neoplasms/metabolism
Proto-Oncogene Proteins c-myc/biosynthesis
[Mh] MeSH terms secundary: Allografts
Disease-Free Survival
Hematopoietic Stem Cell Transplantation
Humans
Immune System Diseases/pathology
Immune System Diseases/therapy
Neoplasms/pathology
Neoplasms/therapy
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Biomarkers, Tumor); 0 (MYC protein, human); 0 (Proto-Oncogene Proteins c-myc)
[Em] Entry month:1803
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180101
[St] Status:MEDLINE

  10 / 8435 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29250862
[Au] Autor:Kakuta R; Yamagami J; Funakoshi T; Takahashi H; Ohyama M; Amagai M
[Ad] Address:Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
[Ti] Title:Azathioprine monotherapy in autoimmune blistering diseases: A feasible option for mild to moderate cases.
[So] Source:J Dermatol;45(3):334-339, 2018 Mar.
[Is] ISSN:1346-8138
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Azathioprine (AZP) is used as a corticosteroid (CS)-sparing medication to treat autoimmune blistering diseases. In this study, we examined the efficacy of AZP and the feasibility of using AZP monotherapy (without CS) to treat pemphigus and pemphigoid. We performed a retrospective study of 10 Japanese patients (seven with pemphigus and three with pemphigoid) with mild to moderate disease activity who had been treated using AZP. The treatment efficacy was evaluated based on decreases in the disease activity scores and autoantibody titers. The results demonstrate that seven out of 10 cases (70%) were treated successfully using AZP monotherapy with no severe adverse effects. The disease activity scores of the successfully-treated patients decreased to zero after 1-37.5 months (average, 11.9) and the average disease activity scores in these cases decreased significantly at 2 months (38.2 ± 36.6%) compared with the scores of the three patients who required additional systemic CS therapy (77.5 ± 3.5%) (P < 0.05). Additionally, the autoantibody titers of five cases treated successfully using AZP decreased by half at 6 months. In conclusion, our findings suggest that AZP monotherapy is a viable treatment option for mild to moderate pemphigus and pemphigoid.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[St] Status:In-Process
[do] DOI:10.1111/1346-8138.14173


page 1 of 844 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information